Hyperthermia News - February 2017
Dr. Sennewald
Success for Clinical Hyperthermia in Switzerland 

We would like to draw your attention to the fact that hyperthermia with radiotherapy is once again covered by Swiss health insurance.

As of January 1st, the costs of hyperthermia in clinical oncology for certain indications and in combination with radiation therapy are to be reimbursed by the patients’ mandatory health insurers. This was stipulated by the Swiss Federal Department of Health in a decision made mid-December last year, clearly signaling acceptance of this method of cancer treatment.

Among the catalog of indications covered are inoperable breast cancer, combining standard treatment with superficial hyperthermia, and bladder cancer when combined with regional deep hyperthermia. Moreover, the new stipulation means those patients with a tumor recurrence in a region previously treated with radiotherapy can receive the treatment again in combination with hyperthermia.

This decision is mainly due to the pioneering work of Professor Stephan Bodis, who heads the Radiation Oncology Center at Aarau Cantonal Hospital in Switzerland. He and his team have been working to achieve this reimbursement for several years now.

The result is good news for hyperthermia and for the fight against cancer in general.
Hyperthermia Press Conference

Following the Clinical Hyperthermia Conference (Program PDF) held in Vienna last October, the Society of Physicians (Gesellschaft der Ärzte) hosted a press conference on recent advances in hyperthermia combined with chemo- or radiotherapy. Renowned speakers explained how the treatment mobilizes the immune system and enhances the overall survival rate. The experts also called for the implementation of hyperthermia in a recognized clinic in Austria. The speakers' contributions are available from the Society’s website.
 Prof. Dr. med. Niloy R. Datta
Prof. Niloy R. Datta from Cantonal Hospital Aarau, Towards Hyperthermia as the 4th Pillar in Oncology: Some representative case illustrations.

 Duration: 10:27 min., English
 em. O. Univ. Prof. Dr. Dr. h. c. mult. Rainer Rienmüller
Prof. Rainer Rienmüller from University Hospital Graz, Klinische Hyperthermie (Regionale, tiefe Hyperthermie mit MR kontrollierter Temperaturmessung).

 Duration: 8:51 min., German
Prof. Dr. med. Rolf D. Issels
Prof. Rolf D. Issels from University Hospital Munich Großhadern, Hyperthermie.

 Duration: 7:47 min., German
Priv.-Doz. Dr. med. Rüdiger Wessalowski
Dr. Rüdiger Wessalowski from University Hospital Düsseldorf, Hyperthermie in der Pädiatrischen Onkologie.

 Duration: 5:47 min., German
Hyperthermia in the News

The German daily newspaper Tagesspiegel published last October a special issue Gesund (Healthy) dedicated to oncology.

In a three-page interview Hitze macht die Therapie wirksamer (Heat improves the efficacy of treatment), Dr. Pirus Ghadjar and Dr. Jacek Nadobny discuss their work with hyperthermia at Berlin’s Charité University Hospital and the importance of adhering to international quality standards.
Hyperthermia in the news
 PDF, available in German
Dr. Sennewald Medizintechnik GmbH

Dr. Sennewald Medizintechnik GmbH was founded in 1985 by Dr. Gerhard Sennewald in Munich with the goal of discovering trendsetting electro-medical systems providing innovative and beneficial medical treatments and introducing them in Europe. From the beginning, cancer therapy was at the forefront of the company, with a focus on regional and local hyperthermia.

Martin Wadepohl,
Manager International Sales

Dirk Lutter, Sales Manager

Monica Sennewald, Marketing Director

Dr. Gerhard Sennewald, CEO
Copyright © 2017 Dr. Sennewald Medizintechnik GmbH, All rights reserved.

Fon: +49 (0)89 542143-20
Mobile: +49 (0)172 9111479
Fax: +49 (0)89 542143-30
EFAX:    +49 (0)89 95464138

Geschäftsführer: Dr. Dipl.-Ing. Gerhard W. Sennewald
Handelsregister: Amtsgericht München HRB 75654
USt-IdNr.: DE 129331634
WEEE-Reg.-Nr.: DE 22905506